Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - amlodipine (as amlodipine besilate ph. eur.); olmesartan medoxomil - film-coated tablet - 40/5 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - amlodipine (as amlodipine besilate ph. eur.); olmesartan medoxomil - film-coated tablet - 40/10 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - olmesartan medoxomil; amlodipine - film-coated tablet - 20/5 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - olmesartan medoxomil; amlodipine - film-coated tablet - 40/10 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - olmesartan medoxomil; amlodipine - film-coated tablet - 40/5 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - olamlo hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 20/5 mg/mg - angiotensin ii antagonists and calcium channel blockers

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 40/5 - angiotensin ii antagonists and calcium channel blockers

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - olmesartan medoxomil, amlodipine besilate - film coated tablet - 40/10 - angiotensin ii antagonists and calcium channel blockers

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.9 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; povidone; lactose monohydrate; isopropyl alcohol; silicified microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - olamlo hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.